Dyne Therapeutics, Inc. (NASDAQ: DYN) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $47.00 price target on the stock.
Dyne Therapeutics, Inc. (NASDAQ: DYN) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $31.00 price target on the stock.
We're Hopeful That Dyne Therapeutics (NASDAQ:DYN) Will Use Its Cash Wisely [Yahoo! Finance]
Dyne Therapeutics, Inc. (NASDAQ: DYN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $36.00 price target on the stock.
Dyne Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights [Yahoo! Finance]